IL-6: A Marker for AML Chemo Sensitivity

Last updated: June 30, 2024
Sponsor: Fujian Medical University Union Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Allergy

Allergy (Pediatric)

Allergies & Asthma

Treatment

N/A

Clinical Study ID

NCT06486350
AML-IL6
  • Ages > 18
  • All Genders

Study Summary

Acute myeloid leukemia (AML) is a clonal malignancy that arises from the primitive hematopoietic cells within the hematopoietic system. According to SEER cancer statistics, the 5-year survival rate for AML patients stands at a concerning 30%. Despite therapeutic advancements, the development of chemotherapy resistance and the risk of disease relapse pose significant barriers to curative outcomes. Evidence has linked elevated interleukin-6 (IL-6) levels in plasma and bone marrow to a poorer prognosis in AML, with IL-6 potentially fostering chemotherapy resistance through the enhancement of fatty acid uptake and the induction of stromal-like morphological changes in AML cells. However, the role of IL-6 as a potential biomarker for monitoring chemotherapy sensitivity in AML has not been fully elucidated. This study seeks to investigate the correlation between IL-6 levels in bone marrow supernatant and the sensitivity to chemotherapy, offering a clinical perspective that could pave the way for improved prognostic markers and personalized treatment strategies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Clinical diagnosis aligns with the "Chinese guidelines for diagnosis and treatmentof adult acute myeloid leukemia (not APL) (2023)";

  2. All patients are experiencing their first onset of the disease and have not receivedany related chemotherapy prior to the study;

  3. Patients participate in the study accompanied by family members and sign informedconsent documents.

Exclusion

Exclusion Criteria:

  1. Patients with concurrent malignancies requiring treatment;

  2. Presence of infectious diseases, including SARS, viral hepatitis, or HIV/AIDS;

  3. Major surgery performed within the last 21 days;

  4. Performance Status (PS) score >3;

  5. Severe liver or kidney dysfunction or serious infection;

  6. Severe psychiatric conditions that impair understanding of the study protocol orvoluntary withdrawal.

Study Design

Total Participants: 72
Study Start date:
October 01, 2023
Estimated Completion Date:
June 30, 2025

Study Description

In this prospective study, we will collect bone marrow supernatant samples from patients diagnosed with Acute Myeloid Leukemia (AML) to evaluate the levels of Interleukin-6 (IL-6). Our aim is to explore whether elevated IL-6 levels can serve as a predictive biomarker for poor treatment outcomes following standard chemotherapy regimens. The findings may help in stratifying patient risk and personalizing therapeutic approaches in AML treatment.

Connect with a study center

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian 350001
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.